JACC This Week

Join Dr. Harlan Krumholz and Dr. Milton Packer as they discuss the groundbreaking SUMMIT trial, a study poised to redefine treatment for heart failure with preserved ejection fraction (HFpEF) linked to obesity. Dive into the trial's unique methodology, compelling results, and transformative implications for patient care.

Harlan Krumholz, editor-in-chief of JACC, provides a wrap-up of the JACC papers at the AHA Scientific Sessions in Chicago in 2024. JACC's Obesity Revolution page features various trials to provide perspectives on obesity, including SUMMIT, LookAHEAD, and SELECT. Other studies featured include the DANGER trial; REALIZE-K; AMPLATZER; HELIOS-B; a study on sedentary behaviors from the UK Biobank; syst...

JACC Associate Editor Michelle M. Kittleson, MD, PhD, FACC, interviews author Mikhail Kosiborod, MD, FACC about his REALIZE-K study published in JACC and presented at AHA. In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalemia and down-titration/discontinua...

JACC Associate Editor Marc P. Bonaca, MD, FACC, speaks with author Subodh Verma, MD, PhD, and A. Michael A. Lincoff, MD, FACC, about this brief report published in JACC and presented at AHA. Following CABG surgery there remains a markedly high risk of persistent ischemic events, heart failure, and mortality. Semaglutide consistently reduced all cardiovascular outcomes in this population.

JACC Associate Editor Neha J. Pagidipati, MD, FACC, speaks with author Christopher M. Kramer, MD, FACC about this substudy of the SUMMIT trial published in JACC and presented at AHA, demonstrating that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes...

JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, talks with authors Scott Solomon, MD, FACC and. Marianna Fontana, MD, about their study published in JACC and presented at AHA. Outpatient worsening heart failure (HF) (oral diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. In this pre-specified analysis...

JACC Deputy Editor Erica S. Spatz, MD, FACC, joins author Rishi Wadhera, MD, to discuss his paper on rural and urban differences in cardiovascular mortality in the United States, and the impact of the COVID-19 pandemic.

JACC Associate Editor Muthiah Vaduganathan, MD speaks with author Ambarish Pandey, MD about the LookAHEAD trial published in JACC and presented at AHA. Among adults with T2D and overweight/obesity in the Look Action for Health in Diabetes (AHEAD) trial, an intensive lifestyle intervention targeting weight loss led to sustained reductions in hs-cTnT at 1- and 4-year follow-up, and a rise in NT-proB...

JACC: Associate Editor Celina Yong, MD, interviews author Jacob Eifer Møller, PhD about his DANGER SHOCK paper presented at AHA and published in JACC. The DanGer Shock trial demonstrated reduced mortality in patients with STEMI-related cardiogenic shock treated with a microaxial flow pump (mAFP). This secondary analysis assessed whether age affected survival benefits. Mortality increased increment...

JACC Associate Editor Marc P. Bonaca, MD, FACC, has a discussion with author Sotirios Tsimikas, MD, FACC about this study on phospholipids presented at AHA and published in JACC. In MESA, both OxPL-apoB and Lp(a) were independently associated with prevalent AVC with a significant interaction between the two (p less than 0.01). OxPL-apoB and Lp(a) were associated with incident AVC at 9.5 years when...

JACC Associate Editor Xiaoxi Yao, MPH, MS, PhD, FACC, interviews author Shaan Khurshid, MD and Ezimamaka Ajufo, MD, about their study on sedentary behavior presented at AHA and published in JACC. Beyond serving as a marker for insufficient physical activity, sedentary behavior may directly affect risk of future cardiovascular (CV) disease. In 89,530 UK biobank participants, greater accelerometer-m...

JACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among t...

JACC Associate Editor Jason H. Wasfy, MD, MPhil, FACC interviews author Vinay Kini, MD, FACC about this hospital integration study published in JACC and presented at AHA. Cardiologist employment by hospitals is increasing, but the impact on care quality is not well understood. The study identified cardiologists who cared for acute myocardial infarction or heart failure patients between 2008-2019....

JACC Deputy Editor Erica S. Spatz, MD, FACC, joins author Rishi Wadhera, MD, to discuss his paper on rural and urban differences in cardiovascular mortality in the United States, and the impact of the COVID-19 pandemic.

In this episode, Dr. Valentin Fuster reviews a study on the impact of long-term drug treatment discontinuation in heart failure patients with reduced ejection fraction. He breaks down four pathways of drug withdrawal—ranging from immediate clinical worsening to long-term deterioration—emphasizing the importance of avoiding unnecessary interruptions in treatment to prevent significant health risks.

In this episode, Dr. Valentin Fuster reviews a recent study exploring the clinical overlap between heart failure with preserved ejection fraction (HFpEF) and Group 1 pulmonary hypertension. The study identifies a subset of patients with pulmonary hypertension who have a higher risk of heart failure and worse outcomes, emphasizing the need for further investigation into whether pulmonary hypertensi...

In this episode, Dr. Valentin Fuster reviews an exploratory analysis from the 80s2 trial, which examined CSL 112's impact on ischemic events after acute myocardial infarction. While CSL 112 didn't significantly reduce cardiovascular death or stroke in the short term, the study found promising long-term benefits, suggesting that enhancing cholesterol efflux could be a valuable approach for reducing...

In this episode, a study on pediatric heart transplant recipients highlights the decreasing prevalence of recurrent rejection, yet finds that children who experience multiple rejection episodes face a significantly higher risk of graft loss. Notably, racial disparities were observed, with Black children showing poorer outcomes, suggesting the need for standardized care protocols and a focus on eli...

In this episode, Dr. Valentin Fuster discusses a groundbreaking study examining how both social determinants of health and polygenic risk scores independently contribute to the risk of coronary heart disease (CHD). The research highlights how factors like income, education, and food insecurity are linked to higher CHD risk, particularly among Black and Hispanic populations, while emphasizing the n...

In the November 26, 2024 issue of JACC, Dr. Valentin Fuster highlights four pivotal studies in cardiovascular research. The first explores the independent roles of social determinants of health and polygenic risk scores in coronary heart disease, while the second assesses the impact of recurrent rejection on pediatric heart transplant outcomes. The third paper examines the effects of CSL 112 infus...

Join Harlan Krumholz, editor-in-chief of JACC, as he highlights groundbreaking cardiovascular science presented at this year's American Heart Association Scientific Sessions. From obesity-related heart failure to innovations in stroke prevention and disparities in care, this episode delves into pivotal studies shaping the future of cardiology and their real-world clinical implications.

In this episode, Dr. Valentin Fuster explores the evolution of leadless cardiac pacing over the past decade, highlighting its safety, efficacy, and growing role in treating heart patients. He reviews key advancements, including single and dual-chamber leadless pacemakers, ongoing innovations, and future developments, emphasizing their potential to replace traditional pacemakers and improve patient...

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on the embryological origins of atrial fibrillation triggers, which could help refine treatment strategies for the condition. The research highlights how genetic factors linked to specific atrial regions, like the sinus venosus and primitive atrium, influence arrhythmia recurrence after ablation, potentially paving the way for m...

In this podcast, Dr. Valentin Fuster reviews a groundbreaking study on intraoperative conduction mapping to prevent postoperative atrioventricular block (AVB) in children with complex congenital heart disease. The study highlights how mapping the His bundle during surgery significantly reduces the need for pacemakers, particularly in high-risk populations like those with Heterotaxy syndrome and no...

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on Brugada Syndrome, exploring how non-modifiable risk factors—such as male sex, SCN 5A mutations, and polygenic risk scores—can predict life-threatening arrhythmic events in patients. The research, published in JACC (November 2024), offers new insights into personalized risk assessment for this inherited arrhythmia syndrome, th...